Migraine drug rimegepant's pregnancy safety under review
NCT ID NCT05198245
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether the migraine medication rimegepant is safe to take during pregnancy. Researchers will compare pregnancy outcomes in women who took rimegepant to those who did not. The study includes women aged 16 to 49 with migraine. However, only one person has been enrolled so far, so results are very limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
rimegepant
What this could lead to
If successful, this study could provide important safety information about using rimegepant during pregnancy, helping doctors and patients make informed decisions.
What could go wrong
This is a small, retrospective study with only one enrolled participant, so results may not be reliable or generalizable to all pregnant women with migraine.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIGRAINE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
New York, New York, 10001, United States